Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Leukemia, Myeloid, Acute 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Biphenotypic, Acute 1Diffuse Intrinsic Pontine Glioma 1Blastic Plasmacytoid Dendritic Cell Neoplasm 1

Interventions

Dexamethasone 87daratumumab 49Lenalidomide 49pomalidomide 33Bortezomib 32Cyclophosphamide 31carfilzomib 25Calcium Dobesilate 21talquetamab 19fludarabine 18isatuximab 16iberdomide 16Magnetic Resonance Spectroscopy 16Specimen Handling 15Biopsy 14selinexor 12Melphalan 11belantamab mafodotin 10dexamethasone acetate 9dexamethasone 21-phosphate 8elotuzumab 7auricularum 7venetoclax 6tocilizumab 5fludarabine phosphate 5X-Rays 5Blood Specimen Collection 5ruxolitinib 4Methylprednisolone 4Injections 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Multiple Myeloma × Fluid Therapy × Clear all
NCT05847569 2026-02-03

Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma

Mayo Clinic

Phase 2 Recruiting
62 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡